Varlilumab

Varlilumab (INN;[1] development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies.[2] It is an anti-CD27 antibody and helps activate T-cells.[3]

Varlilumab
Monoclonal antibody
Type?
SourceHuman
TargetCD27
Clinical data
Other namesCDX-1127
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6486H9992N1740O2022S42
Molar mass146043.96 g·mol−1

This drug was developed by Celldex Therapeutics.

It (in combination with ONT-10) has undergone a phase 1B clinical trial for advanced breast or ovarian cancer.[4] In combination with anti-PD-1 nivolumab it has undergone a phase 1/2 trial for advanced refractory solid tumours.[5]

References
  1. World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Varlilumab, American Medical Association.
  3. Varlilumab-Opdivo Combo Stabilizes or Shrinks Tumors in 80% of Solid-cancer Patients, Trial Shows. June 2017
  4. Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
  5. A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.